[go: up one dir, main page]

MXPA02003484A - Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba. - Google Patents

Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.

Info

Publication number
MXPA02003484A
MXPA02003484A MXPA02003484A MXPA02003484A MXPA02003484A MX PA02003484 A MXPA02003484 A MX PA02003484A MX PA02003484 A MXPA02003484 A MX PA02003484A MX PA02003484 A MXPA02003484 A MX PA02003484A MX PA02003484 A MXPA02003484 A MX PA02003484A
Authority
MX
Mexico
Prior art keywords
synergistic combinations
receptor antagonist
gaba analog
treatment
present
Prior art date
Application number
MXPA02003484A
Other languages
English (en)
Inventor
Singh Lakhbir
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA02003484A publication Critical patent/MXPA02003484A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona metodos de tratamiento usando combinaciones sinergisticas de un antagonista de receptor de NK1 y un analogo de GABA, y composiciones farmaceuticas y productos que contienen el antagonista de receptor de NK1 y el analogo de GABA. La presente invencion tambien proporciona el uso de un antagonista de receptor de NK1 y un analogo de GABA para la fabricacion de un medicamento para el tratamiento o la prevencion del dolor cronico.
MXPA02003484A 1999-10-07 2000-10-05 Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba. MXPA02003484A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (1)

Publication Number Publication Date
MXPA02003484A true MXPA02003484A (es) 2004-09-10

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02003484A MXPA02003484A (es) 1999-10-07 2000-10-05 Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.

Country Status (38)

Country Link
EP (2) EP1221950B1 (es)
JP (2) JP2003510356A (es)
KR (1) KR20020060192A (es)
CN (1) CN1387434A (es)
AP (1) AP2002002501A0 (es)
AR (1) AR029646A1 (es)
AT (1) ATE269072T1 (es)
AU (2) AU7663300A (es)
BG (1) BG106548A (es)
BR (1) BR0014598A (es)
CA (1) CA2385930A1 (es)
CO (1) CO5280195A1 (es)
CR (1) CR6614A (es)
CZ (1) CZ20021116A3 (es)
DE (1) DE60011650T2 (es)
DK (1) DK1221950T3 (es)
EA (1) EA004266B1 (es)
EE (1) EE200200185A (es)
ES (1) ES2220542T3 (es)
GT (1) GT200000166A (es)
HR (1) HRP20020286A2 (es)
HU (1) HUP0203466A3 (es)
IL (1) IL148965A0 (es)
IS (1) IS6318A (es)
MA (1) MA26826A1 (es)
MX (1) MXPA02003484A (es)
NO (1) NO20021625D0 (es)
NZ (1) NZ517949A (es)
OA (1) OA12063A (es)
PA (1) PA8504301A1 (es)
PE (1) PE20010708A1 (es)
PL (1) PL357498A1 (es)
PT (1) PT1221950E (es)
SK (1) SK4542002A3 (es)
TR (1) TR200200913T2 (es)
UY (1) UY26376A1 (es)
WO (2) WO2001024792A1 (es)
ZA (1) ZA200202675B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0934061T1 (en) 1996-07-24 2003-10-31 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
CA2483093A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Use of milnacipran or a pharmaceutically acceptable salt thereof for treating chronic low back pain
EP1558218A1 (en) * 2002-10-08 2005-08-03 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
DK1492519T3 (da) * 2003-03-21 2007-03-05 Dynogen Pharmaceuticals Inc Fremgangsmåder til behandling af lidelser i den nedre urinvej ved anvendelse af alfa-2-delta-underenhedscalciumkanalsmodulatorer med glat muskel-modulatorer
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
EP2599487B1 (en) 2010-07-30 2015-04-01 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
MX2021011550A (es) 2019-03-26 2021-10-26 Orion Corp Formulaciones de pregabalina y uso de las mismas.
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
WO1998015277A2 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Cns-penetrant nk-1 receptor antagonists as antidepressant and/or an anti-anxiety agents
AU729708B2 (en) * 1996-12-02 2001-02-08 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
AR029646A1 (es) 2003-07-10
IL148965A0 (en) 2002-11-10
CN1387434A (zh) 2002-12-25
PE20010708A1 (es) 2001-07-27
WO2001024792A9 (en) 2002-09-06
EE200200185A (et) 2003-04-15
ATE269072T1 (de) 2004-07-15
MA26826A1 (fr) 2004-12-20
EP1221950B1 (en) 2004-06-16
UY26376A1 (es) 2000-12-29
EP1221950A1 (en) 2002-07-17
HUP0203466A2 (hu) 2003-02-28
PL357498A1 (en) 2004-07-26
IS6318A (is) 2002-03-21
NO20021625L (no) 2002-04-05
CA2385930A1 (en) 2001-04-12
AU7663300A (en) 2001-05-10
GT200000166A (es) 2002-03-30
DE60011650T2 (de) 2005-07-14
CZ20021116A3 (cs) 2003-05-14
WO2001024792A1 (en) 2001-04-12
OA12063A (en) 2006-05-03
BR0014598A (pt) 2002-06-11
AP2002002501A0 (en) 2002-06-30
DK1221950T3 (da) 2004-09-20
BG106548A (en) 2002-12-29
JP2003510355A (ja) 2003-03-18
SK4542002A3 (en) 2003-09-11
HRP20020286A2 (en) 2003-08-31
NO20021625D0 (no) 2002-04-05
TR200200913T2 (tr) 2002-09-23
PA8504301A1 (es) 2002-08-26
JP2003510356A (ja) 2003-03-18
WO2001024791A1 (en) 2001-04-12
ZA200202675B (en) 2003-04-15
EA200200303A1 (ru) 2002-08-29
CO5280195A1 (es) 2003-05-30
EA004266B1 (ru) 2004-02-26
NZ517949A (en) 2003-08-29
HUP0203466A3 (en) 2005-03-29
EP1233766A1 (en) 2002-08-28
PT1221950E (pt) 2004-08-31
DE60011650D1 (de) 2004-07-22
KR20020060192A (ko) 2002-07-16
CR6614A (es) 2003-12-04
AU1696201A (en) 2001-05-10
ES2220542T3 (es) 2004-12-16

Similar Documents

Publication Publication Date Title
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
AU2003301190A1 (en) Administration of capsaicinoids
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
HK1040945A1 (zh) 包含曲马多物质和选择性cox-2抑制剂药物的组合物
MY127980A (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
RS20050344A (en) Treatment for hemorrhagic shock
MXPA02003484A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba.
PL374443A1 (en) Novel pyrimidineamide derivatives and the use thereof
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
MY138502A (en) Novel alkansulfonamides as endothelin antagonists
GB9917290D0 (en) Pharmaceutical composition
HUP0203309A3 (en) Therapeutic combinations of (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino(2,3)-e indol-8-one and neuroleptics for treatment or prevention of phychotic disorders and pharmaceutical compositions containing them
IL156144A0 (en) Novel therapeutic use of a thienylcyclohexylamine derivative
DOP2000000076A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un análogo estructural de gaba. (synergistic combinations of a nki receptor antagonist and a gaba structural analog)
MXPA03010920A (es) Uso de alconil l- carnitina para preparacion de medicamento para tratar anhedonia.
ECSP003696A (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba
UA36137A (uk) Спосіб лікування хворих на хронічне легеневе серце
MX9707719A (es) Preparado en combinacion que contiene tramadol y un antagonista del canal de calcio.

Legal Events

Date Code Title Description
FG Grant or registration